TO THE EDITOR
The recent article by Bargagli et al. about the evaluation of Calgranulin B (S100A9) levels in the bronchoalveolar lavage fluid of patients with interstitial lung diseases was highly interesting and thought provoking [1] . Bargagli et al. have clearly shown that calgranulin B is involved in the evolution and progression of chronic lung diseases. Interestingly, calgranulin B is also rapidly evolving as a significant marker of a number of other systemic non-inflammatory conditions especially systemic malignances.
For instance, calgranulin B is increased in the stools of patients with colorectal cancer [2] . Similarly, Ott et al. have even demonstrated that fluid drawn from cystic malignant ovarian lesions express calgranulin B in sharp contrast to fluid drawn from benign cystic lesions which do not demonstrate calgranulin B [3] . Similarly, increased expression of calgranulin B is seen in biopsies of patients with Barretts esophagitis who demonstrate high grade dysplasia [4] while similar increased expression of calgranulin B is also seen in head and neck tumors such as cholesteatomas [5] . Increased expression of the calgranulin B gene has also been noted in pulmonary carcinomas in conjunction with increased expression of other genes such as apolipoprotein E [6] . Similarly, matrix-assisted laser desorption ionization-time of flight-mass spectroscopy (MALDI-TOF-MS) analysis of voided urine following prostatic massage from patients with prostate cancer reveals increased levels of calgranulin B/MRP-14 [7] .
These examples clearly indicate the massive diagnostic as well as prognostic potential of calgranulin B. Clearly, there is a need for further large scale studies to elaborate the exact sensitivity and specificity of calgranulin B as a diagnostic marker in these various conditions so as to extend its use from beyond clinical studies to the realm of routine oncology.
